Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Tesch

Showing results (51-60 of 171) with videos related to

Pageof 18
Sort By:
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|August 3, 2016
CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patientsBrigitte Rack, Julia Jückstock, Elisabeth Trapp, et al.
Onkologie|April 15, 2010
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health systemMichael P Lux, Achim Wöckel, Agnes Benedict, et al.
Breast Cancer Research and Treatment|June 14, 2024
The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancerChristian Jackisch, Louiza Anastasiadou, Sebastian Aulmann, et al.
Journal of Cancer Research and Clinical Oncology|March 8, 2023
Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in GermanyAndreas Schmidt, Christiane Bernhardt, Dieter Bürkle, et al.
Journal of Bone Oncology|December 6, 2018
The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trialPeyman Hadji, Oliver Stoetzer, Thomas Decker, et al.
Journal of the National Cancer Institute|May 17, 2014
Circulating tumor cells predict survival in early average-to-high risk breast cancer patientsBrigitte Rack, Christian Schindlbeck, Julia Jückstock, et al.
Breast Cancer Research and Treatment|July 13, 2010
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trialIsabell Witzel, Sibylle Loibl, Gunter von Minckwitz, et al.
International Journal of Cancer|July 12, 2018
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trialHans Tesch, Oliver Stoetzer, Thomas Decker, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2021
Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapyFrederik Marmé, Christine Solbach, Laura Michel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2018
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)Michael Untch, Gunter von Minckwitz, Bernd Gerber, et al.
Pageof 18

Showing results (51-60 of 171) with videos related to

Sort By:
Pageof 18
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|August 3, 2016
CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patientsBrigitte Rack, Julia Jückstock, Elisabeth Trapp, et al.
Onkologie|April 15, 2010
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health systemMichael P Lux, Achim Wöckel, Agnes Benedict, et al.
Breast Cancer Research and Treatment|June 14, 2024
The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancerChristian Jackisch, Louiza Anastasiadou, Sebastian Aulmann, et al.
Journal of Cancer Research and Clinical Oncology|March 8, 2023
Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in GermanyAndreas Schmidt, Christiane Bernhardt, Dieter Bürkle, et al.
Journal of Bone Oncology|December 6, 2018
The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trialPeyman Hadji, Oliver Stoetzer, Thomas Decker, et al.
Journal of the National Cancer Institute|May 17, 2014
Circulating tumor cells predict survival in early average-to-high risk breast cancer patientsBrigitte Rack, Christian Schindlbeck, Julia Jückstock, et al.
Breast Cancer Research and Treatment|July 13, 2010
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trialIsabell Witzel, Sibylle Loibl, Gunter von Minckwitz, et al.
International Journal of Cancer|July 12, 2018
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trialHans Tesch, Oliver Stoetzer, Thomas Decker, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2021
Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapyFrederik Marmé, Christine Solbach, Laura Michel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2018
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)Michael Untch, Gunter von Minckwitz, Bernd Gerber, et al.
Pageof 18